泊奈莫德长期治疗复发缓解型多发性硬化:随机2b期核心与扩展研究结果
本分析基于2b期核心与扩展研究,评估泊奈莫德10、20、40 mg的剂量反应及20 mg长期疗效与安全性。464例患者随机分组,核心期24周,扩展期至432周。20 mg治疗约8年维持低疾病活动度,确认复发年化率为0.154,64%以上患者无确认复发,未发现新安全性问题。
要点
- 泊奈莫德20 mg长期治疗复发缓解型多发性硬化约8年,确认复发年化率为0.154。
- 至第432周,Kaplan-Meier确认复发估计值为43.9%,6个月确认残疾累积为20.4%。
- 最常见不良事件为鼻咽炎(30%)、头痛(24%)和上呼吸道感染(21%)。
核心结论
- 泊奈莫德20 mg对多发性硬化疾病控制的效果维持约8年,未发现新的安全性问题。
研究设计与样本
- 核心研究为随机2b期研究,464例复发缓解型多发性硬化患者按1:1:1:1随机接受安慰剂(n=121)、10 mg(n=108)、20 mg(n=116)或40 mg泊奈莫德(n=119)每日一次治疗24周。
- 完成核心研究的患者进入扩展研究,扩展研究设治疗期1(TP1,至96周)及TP2和TP3(至432周)。
- 40 mg剂量因耐受性低在TP1结束时停用,10 mg剂量因较20 mg获益风险比更低在TP2结束时停用;TP2期间所有患者接受10或20 mg,TP3期间接受20 mg。
- 共435例患者在核心和/或扩展研究期间任何时间接受至少1剂泊奈莫德(首次随机剂量:10 mg=139,20 mg=145,40 mg=151)。
- 截至2019年3月31日,214例患者仍在接受泊奈莫德治疗;泊奈莫德暴露时间中位数(范围)为7.95(0-9.36)年。
主要发现
- 泊奈莫德20 mg从核心研究至TP3结束,与持续低临床活动度相关:确认复发年化率为0.154,第432周确认复发的Kaplan-Meier估计值为43.9%,6个月确认残疾累积为20.4%。
- 泊奈莫德20 mg从核心研究至TP3结束,与持续低MRI疾病活动度相关,超过64%的患者保持无确认复发。
- 最常见不良事件为鼻咽炎(30%)、头痛(24%)和上呼吸道感染(21%)。
关键数值与推荐
- 泊奈莫德20 mg从核心研究至TP3结束,确认复发年化率为0.154。
- 第432周确认复发的Kaplan-Meier估计值为43.9%,6个月确认残疾累积为20.4%。
- 超过64%的患者保持无确认复发。
- 最常见不良事件:鼻咽炎30%、头痛24%、上呼吸道感染21%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the dose-response relationship of 10, 20, and 40 mg ponesimod and long-term efficacy and safety of ponesimod 20 mg using an analysis of combined data from the phase 2 Core and Extension studies in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS: In the Core study, 464 patients were randomized (1:1:1:1): placebo (n = 121), 10 mg (n = 108), 20 mg (n = 116), or 40 mg ponesimod (n = 119) once daily for 24 weeks. Patients who completed the Core study transitioned into the Extension study, which had treatment period 1 (TP1; up to 96 weeks) and TP2 and TP3 (up to 432 weeks). The 40 mg dose was discontinued due to low tolerability at the end of TP1, and the 10 mg dose was subsequently discontinued due to lower benefit-risk profile vs 20 mg at the end of TP2. All patients received 10 or 20 mg during TP2, followed by 20 mg in TP3. Annualized relapse rate (ARR), 6-month confirmed disability accumulation (CDA), time to first confirmed relapse, MRI outcomes, and safety were evaluated. RESULTS: A total of 435 patients received ≥1 dose of ponesimod (first randomized dose: 10 mg = 139, 20 mg = 145, and 40 mg = 151) at any time during the Core and/or the Extension study. As of March 31, 2019, 214 patients were still on ponesimod treatment. The median (range) of ponesimod exposure was 7.95 (0-9.36) years. Ponesimod 20 mg, from Core up to the end of TP3, was associated with sustained low clinical activity (ARR for confirmed relapses: 0.154; at week 432, Kaplan-Meier estimate for confirmed relapse was 43.9%, and 6-month CDA was 20.4%) and MRI disease activity, and over 64% of patients remained free of a confirmed relapse. Most common adverse events were nasopharyngitis (30%), headache (24%), and upper respiratory tract infection (21%). CONCLUSION: The effects on multiple sclerosis disease control were maintained with ponesimod 20 mg for approximately 8 years with no new safety concerns identified. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that in individuals with RRMS, long-term treatment with ponesimod 20 mg was associated with a sustained low annualized confirmed relapse rate (0.154 at week 432), with 64% of patients remaining relapse-free. TRIAL REGISTRATION INFORMATION: EudraCT Number 2008-006786-92 (Core study) and EudraCT Number 2009-011470-15 (Extension study).
引用
- Freedman MS, Pozzilli C, Havrdova EK, et al. Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results From Randomized Phase 2b Core and Extension Studies. Neurology. 2022. PMID: 35667837. doi:10.1212/WNL.0000000000200606
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。